News | Congenital Heart | May 06, 2015

Age, Valve Type Key Determinants for Congenital Re-Intervention

Younger, smaller children at greater risk for complications following pulmonary valve replacement

pulmonary valve replacement, congenital, re-intervention, age, PVR

May 6, 2015 — A retrospective review of 633 adults and children who underwent bioprosthetic pulmonary valve replacement (PVR) for congenital heart disease between 1996 and 2014 indicated that the risk of re-intervention was five times greater for children than adults. In addition, the likelihood of re-intervention decreased by 10 percent for each increasing year of age at surgery. Valve type was another important determinant of re-intervention, according to Rio S. Nomoto, BA, medical student at Tufts University School of Medicine, who presented the results of this research at the 95th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle on April 28.

PVR is recommended for both asymptomatic and symptomatic patients with CHD who have increased risk for right ventricular dilation and dysfunction. These patients may exhibit exercise intolerance, arrhythmia and sudden cardiac events. Pulmonary regurgitation is a common indication for PVR.

“In this comprehensive series, we have identified specific valve type and all measures related to younger patient age at surgery to be important predictors of re-intervention,” explained lead investigator Christopher W. Baird, M.D., of the Department of Cardiac Surgery at Boston Children’s Hospital of Harvard Medical School. The researchers also found that patients who were small for their age were much more likely to experience valve failure, suggesting that these children merit more intensive long-term follow-up.

In this group of 633 patients, the median age at surgery was 17.5 years, and 49 percent of the patients were younger than 18 years. Eight patients were infants. Sixty-eight percent of cases had a diagnosis of Tetralogy of Fallot. The median follow-up was 2.9 years.

Six percent of patients (44) required re-intervention. Of these, 17 underwent a surgical re-intervention and 27 had cardiac catheterization to replace the pulmonary valve. Most events precipitating re-intervention happened at least three years after initial surgery. Thirty patients required more than one re-intervention and 19 deaths occurred post-operatively or during follow-up.

Age at surgery was an important predictor of future re-intervention. At five years post-op, the re-intervention rate was 11 percent for patients younger than 12 years, 7 percent for those 12-27 years old and 0 percent for those older than 27 years. At 10 years after surgery, 100 percent of children who had been operated on when they were less than 6 years old required repeat surgery, as did 74 percent of those who had been between 6 and 11 years old; in contrast, the re-intervention rate was 22 percent for those age 12 to 17 years and 10 percent for those between 18 and 26 years old. None of the patients who were 27 years or older at the time of surgery required re-intervention at the 10-year mark, noted Nomoto.

Other factors associated with younger age were also found to be risk factors for re-intervention, such as low body weight, small body surface area and body mass index (BMI). For instance, those younger than 20 years of age with BMI more than two standard deviations below normal were seven times more likely to experience valve failure. “Children with low BMI may merit closer monitoring following PVR or nutritional counseling to increase BMI prior to scheduling surgery,” suggested Baird.

There was also a significant difference in the risk of re-intervention according to valve type. Fifty percent of patients received the Sorin Mitroflow, 35 percent the CE Magna or MagnaEase, 11 percent the CE Perimount and 4 percent porcine values. Of the four valves evaluated, the Sorin Mitroflow exhibited a significantly higher re-intervention rate (17.6 percent) than the others.

Neither larger valve size nor BSA-adjusted valve orifice size predicted re-intervention. The investigators also found that the magnitude of the valve type differences was independent of age.

For more information: www.aats.org

Related Content

Stem Cell Therapy May Offer Treatment for Rare Congenital Cardiac Defect
News | Congenital Heart | February 05, 2018
February 5, 2018 — Children's Hospital Los Angeles announced participation in the first-ever...
Screening for Critical Congenital Heart Disease at Birth Saves Lives
News | Congenital Heart | December 05, 2017
Infant deaths from critical congenital heart disease (CCHD) decreased more than 33 percent in eight states that...
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart | September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
AHA and ACC Publish New Data Dictionary for Ambulatory EHRs in Pediatric and Congenital Cardiology
News | Congenital Heart | July 19, 2017
July 19, 2017 — The American Heart Association (AHA) and the American College of Cardiology (ACC) recently published
New Multi-Center Research Effort to Focus on Early Life Origins of Heart Health
News | Congenital Heart | June 23, 2017
Heart health in children will be the focus of three closely synergistic research projects and an integrated...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart | June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
pediatric cardiomyopathy, management, clinical outcomes, NIH study, Circulation Heart Failure, Children's Hospital of Michigan
News | Congenital Heart | April 04, 2017
A multi-center study done in the United States and Canada may have global applicability for families with children...
Philips, Phoenix Children's Hospital, strategic partnership, congenital heart
News | Congenital Heart | March 07, 2017
Philips and Phoenix Children’s Hospital (Arizona) announced a long-term strategic partnership with a total value of up...
Jaheim Whigham, Lurie Children's Hospital of Chicago, Syncardia 50cc Total Artificial Heart, youngest patient

At 11 years old, Jaheim Whigham (center) is the youngest and smallest patient to receive the 50cc SynCardia temporary Total Artificial Heart. (Photo: Jan Terry, Ann & Robert H. Lurie Children's Hospital of Chicago)

News | Congenital Heart | January 31, 2017
To save the life of an 11-year-old boy, Ann & Robert H. Lurie Children’s Hospital of Chicago has become the first...
congenital heart disease, CHSD, Society of Thoracic Surgeons, public reporting, parent preferences
News | Congenital Heart | January 25, 2017
Survival statistics, surgeon-specific experience and complication rates are the types of information most wanted by...
Overlay Init